Korsana Biosciences, Inc. Common Stock
KRSA
73 hedge funds and large institutions have $41.8M invested in Korsana Biosciences, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 23 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 86 → 73 (-13)
15.3% less ownership
Funds ownership: 71.29% → 55.99% (-15%)
35% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 23
82% less capital invested
Capital invested by funds: $237M → $41.8M (-$195M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$690K |
| 2 |
AC
AWH Capital
Dallas,
Texas
|
+$378K |
| 3 |
TFS
TrustCore Financial Services
Brentwood,
Tennessee
|
+$130K |
| 4 |
D.E. Shaw & Co
New York
|
+$109K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$101K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$27M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.7M |
| 3 |
SPC
Slate Path Capital
New York
|
-$10.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.84M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.81M |
KRSA Hedge Fund Activity: Q4 2019 in Review
73 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q4 2019, worth a combined $41.8M — down 82% from $237M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of KRSA and 15 opened new positions — a net loss of 8 holders — while 17 trimmed existing stakes and 22 added.
The largest buyer was EcoR1 Capital, adding an estimated $690K. The largest seller was Camber Capital Management, exiting entirely with an estimated $27M sold.
- 73 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q4 2019, down from 86 in Q3 2019.
- Funds reported $41.8M of Korsana Biosciences, Inc. Common Stock stock for Q4 2019, down 82% quarter-over-quarter.
- 15 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q4 2019 and 23 closed out, a net change of -8 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q4 2019 was EcoR1 Capital, an estimated $690K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q4 2019 was Camber Capital Management, an estimated $27M sold.
Based on aggregated 13F filings for Q4 2019.